Accordingly, MCT1 (SLC16A1) and MCT4 (SLC16A3) have been reported to play important roles in tumors and are aberrantly highly expressed in several cancers, including breast, colon, pancreatic, glioblastoma, prostate, and renal cell carcinomas, and are involved in the development of antitumor drug resistance (Pinheiro et al., 2008; Fisel, Schaeffeler & Schwab, 2018). Here, SLC16A1 is linked to renal cell carcinoma.